Preclinical Safety

Platelets & Plasma

  • Ciaravino V, Hanover JL, Lin L et al.  Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a one-month intravenous toxicity study in neonatal rats.  Transfusion 2009;49:5:985-94.
    > View abstract
     
  • Lin L, Conlan MG, Tessman J et al.  Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment.  Transfusion 2005;45(10):1610-20.
    > View abstract

Platelets

  • Ciaravino V.  Preclinical safety of a nucleic acid-targeted Helinx compound: a clinical perspective.  Semin Hematol 2001;38(4 Suppl 11):12-9.
    > View abstract
     
  • Ciaravino V, McCullough T, Cimino G.  The role of toxicology assessment in transfusion medicine.  Transfusion 2003;43(10):1481-92.
    > View abstract
     
  • Ciaravino V, McCullough T, Dayan AD.  Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets.  Hum Exp Toxicol 2001;20(10):533-50.
    > View abstract
     
  • Tice RR, Gatehouse D, Kirkland D and Speit G.  The pathogen reduction treatment of platelets with S-59 HCI (amotosalen) plus ultraviolet A light: genotoxicity profile and hazard assessment.  Mutation Research 2007;630:50-68.
    > View abstract

Plasma

  • Ciaravino V, McCullough T, Cimino G, Sullivan T.  Preclinical safety profile of plasma prepared using the INTERCEPT Blood System.  Vox Sang 2003;85(3):171-82.
    > View abstract

RBC

  • North A, Mufti N, Corash L et al.  Preclinical Pharmacokinetic and Toxicology Assessment of Red Blood Cells prepared with S-303 Pathogen Inactivation TreatmentTransfusion 2011 Oct;51(10):2208-18.
    > View abstract

 

Untitled Document